Jane Huang, incoming Prelude Therapeutics president and CMO

BeiGene hema­tol­ogy CMO Jane Huang makes a quick jump to a strug­gling biotech now jug­gling pipeline projects

Just days af­ter we learned that BeiGene CMO of hema­tol­ogy Jane Huang was plan­ning her ex­it, we now know what she’s do­ing next. Pre­lude Ther­a­peu­tics, a lit­tle biotech fo­cused on can­cer R&D, has re­cruit­ed Huang as its next pres­i­dent and CMO — and they’re back­ing up the play with a chunk of eq­ui­ty.

Ac­cord­ing to an SEC fil­ing, the Genen­tech vet is get­ting a $525,000 a year in salary, a bonus worth up to half of that and 150,000 shares that vest over 4 years — a clas­sic com­bo for top ex­ecs. She al­so gets an op­tion on 460,000 shares that will vest over time.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.